The lat­est tem­pest over a dra­mat­ic drug price hike riles two pow­er­ful sen­a­tors — who can't ac­tu­al­ly do any­thing about it

First Nos­trum CEO Nir­mal Mu­lye caught the at­ten­tion of FDA com­mis­sion­er Scott Got­tlieb when he jacked up the price of an old an­tibi­ot­ic from $474.75 to $2,392 last month. Now he has a pair of an­gry US sen­a­tors on the warpath over his con­tro­ver­sial, Mar­tin Shkre­li-like com­ments about the “moral re­quire­ment” of earn­ing mon­ey for his in­vestors and com­par­ing the move to pric­ing art.

Com­ing in from op­po­site sides of the aisle, Claire Mc­Caskill and Su­san Collins let it be known that the orig­i­nal ar­ti­cle from the Fi­nan­cial Times that got the show start­ed had in­censed them. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.